- Home
- MVO vs BOLD Comparison
MVO vs BOLD Comparison
Compare MVO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MVO | BOLD |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 25.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | MVO | BOLD |
|---|---|---|
| Price | $2.17 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 571.9K | 51.0K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.96 |
| 52 Week High | $6.40 | $1.78 |
Technical Indicators
Market Signals| Indicator | MVO | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 47.14 |
| Support Level | $1.11 | $1.10 |
| Resistance Level | $2.42 | $1.19 |
| Average True Range (ATR) | 0.29 | 0.04 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 7.22 | 29.17 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.